All In Biotech

Free tool

FAERS Monitor: Brinsupri

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217673 or its brand name (Brinsupri, Brensocatib). Reports on generic versions are filed under their own applications.

Reports

2,819

Serious

972

34% of reports

Hospitalization

441

Death reported

106

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • therapy interrupted353
  • cough300
  • headache259
  • dyspnoea204
  • hospitalisation183
  • product dose omission issue183
  • pneumonia175
  • rash174
  • alopecia150
  • dry skin146
  • off label use146
  • fatigue134
  • adverse drug reaction127
  • hypertension122
  • productive cough109

Reports by year received

View as table
YearReports
20191
20201
20223
20237
202419
2025268
20262,520

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,340 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy interruptedSignal35337.033.612,321
productive coughSignal10917.114.21,633
adverse drug reactionSignal12710.68.91,093
hospitalisationSignal1838.97.71,282
dry skinSignal1468.27.0916
coughSignal3008.07.21,850
alopeciaSignal1505.74.9582
product dose omission issueSignal1834.64.0527
hypertensionSignal1224.33.6309
pneumoniaSignal1754.03.5402
headacheSignal2593.12.7373
rashSignal1743.02.6231
dyspnoeaSignal2042.72.4221
fatigue1341.31.18
off label use1461.21.17

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.